Across TCGA pan-cancer cohorts, LHFPL3-AS2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated LHFPL3-AS2 data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher LHFPL3-AS2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LHFPL3-AS2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and LUAD show a favorable association.
KIRC, CESC, and LIHC are the cancer types where LHFPL3-AS2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.